Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Deferred Revenue (2016 - 2023)

Theravance Biopharma (TBPH) has disclosed Current Deferred Revenue for 11 consecutive years, with $24000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Current Deferred Revenue changed 0.0% to $24000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $24000.0, a 0.0% change, with the full-year FY2022 number at $24000.0, changed N/A from a year prior.
  • Current Deferred Revenue was $24000.0 for Q3 2023 at Theravance Biopharma, roughly flat from $24000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $43.3 million in Q2 2019 to a low of $24000.0 in Q2 2022.
  • A 5-year average of $13.6 million and a median of $6.7 million in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: crashed 99.58% in 2022, then changed 0.0% in 2023.
  • Theravance Biopharma's Current Deferred Revenue stood at $31.6 million in 2019, then plummeted by 63.51% to $11.5 million in 2020, then plummeted by 74.82% to $2.9 million in 2021, then crashed by 99.17% to $24000.0 in 2022, then changed by 0.0% to $24000.0 in 2023.
  • Per Business Quant, the three most recent readings for TBPH's Current Deferred Revenue are $24000.0 (Q3 2023), $24000.0 (Q2 2023), and $24000.0 (Q1 2023).